Therapeutic effects of cholesterol absorption inhibitor on renal function in patients with chronic kidney disease
Phase 4
- Conditions
- Chronic kidney disease Hypercholesterolemia
- Registration Number
- JPRN-UMIN000002528
- Lead Sponsor
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. History of hypersensitivity to ezechimibe 2. Dialysis patients 3. Severe liver disease 4. Secondary or drug-induced hypercholesterolemia 5. Pregnant or nursing women or women suspect of pregnancy 6. Judged as inappropriate for study by doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Lipid profile including T-cho, LDL-C, HDL-C, TG, and RLP-C. 2) eFGR 3) Urinary albumin excretion
- Secondary Outcome Measures
Name Time Method 1) Glucose profile including FPG, HbA1C, and IRI. 2) Markers of cholesterol synthesis and absorption 3) Markers of oxidative stress including pentosidine and L-FABP 4) CBC and biochemistry including AST, ALT, gammaGTP, BUN, sCr, K, BNP 5) Adverse events